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Global trends and gaps in research related
to latent tuberculosis infection
Liling Chaw1, Lung-Chang Chien2, Justin Wong3, Ken Takahashi4, David Koh1,5 and Ro-Ting Lin6*

Abstract
Background: There is a global commitment to eliminating tuberculosis (TB). It is critical to detect and treat cases of
latent TB infection (LTBI), the reservoir of new TB cases. Our study assesses trends in publication of LTBI-related
research.
Methods: We used the keywords (“latent tuberculosis” OR “LTBI” OR “latent TB”) to search the Web of Science for
LTBI-related articles published 1995–2018, then classified the results into three research areas: laboratory sciences,
clinical research, and public health. We calculated the proportions of LTBI-related articles in each area to three areas
combined, the average rates of LTBI-related to all scientific and TB-related articles, and the average annual percent
changes (AAPC) in rates for all countries and for the top 13 countries individually and combined publishing LTBI
research.
Results: The proportion of LTBI-related articles increased over time in all research areas, with the highest AAPC in
laboratory (38.2%/yr), followed by public health (22.9%/yr) and clinical (15.1%/yr). South Africa (rate ratio [RR] = 8.28,
95% CI 5.68 to 12.08) and India (RR = 2.53, 95% CI 1.74 to 3.69) had higher RRs of overall TB-related articles to all
articles, but did not outperform the average of the top 13 countries in the RRs of LTBI-related articles to TB-related
articles. Italy (RR = 1.95, 95% CI 1.45 to 2.63), Canada (RR = 1.73, 95% CI 1.28 to 2.34), and Spain (RR = 1.53, 95% CI
1.13 to 2.07) had higher RRs of LTBI-related articles to TB-related articles.
Conclusions: High TB burden countries (TB incidence > 100 per 100,000 population) published more overall
TB-related research, whereas low TB burden countries showed greater focus on LTBI. Given the potential
benefits, high TB burden countries should consider increasing their emphasis on LTBI-related research.
Keywords: Tuberculosis, Latent tuberculosis infection, Public health, Prevention, Research governance,
Bibliometric analysis

Background
Tuberculosis (TB) is a bacterial disease that remains one
of the leading causes of mortality worldwide, with an estimated 10 million cases and 1.2 million deaths in 2018 [1].
In 2015, the World Health Organization (WHO) initiated
the End TB Strategy, which aims for a 90% reduction in
TB incidence and a 95% reduction in TB mortality by the
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year 2035 [2]. Currently, the global TB incidence is falling
at an average rate of about 2% per year, which is not fast
enough to meet the milestones set by the End TB Strategy
[1]. In 2018, the first-ever United Nations General Assembly high-level meeting on TB endorsed an ambitious and
powerful political declaration to accelerate progress toward End TB targets. Notably, the political declaration intensified research and innovation as one of the key
strategies to accelerate progress [3]. WHO has developed
a ten-year global action framework for TB research to foster high-quality TB research at both national and global
levels [4].
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One of the targets in the End TB Strategy is 90% preventive treatment coverage, which relates to the detection and treatment of latent TB infection (LTBI) cases
prior to their progression to active TB disease [1]. LTBI
is defined as a state of persistent immune response to
Mycobacterium tuberculosis without clinically manifested evidence of active TB. WHO estimates that 23%
of the world’s population (1.7 billion people) have LTBI,
and a small proportion of these (5–10% of the 1.7 billion
people with LTBI) are expected to progress to develop
TB disease during their lifetimes [1]. Intensifying efforts
to detect and treat LTBI could help reduce the reservoir
of potential TB cases and thus contribute to the reduction and eventual elimination of TB incidence.
Global efforts to intensify TB prevention, control, and research activities have resulted in a large number of scientific
publications about TB. An increase in research activities
has been reported for TB in general [5, 6] and multidrugresistant TB [7]. These reports used a tool called bibliometric analysis that allows tracking and assessment of research
productivity and growth over a period of time. As similar
comprehensive assessments have not been done for LTBI
research, it is unclear whether the global trend in scientific
publications for LTBI has also been increasing. WHO recently published an updated and consolidated guideline for
LTBI programmatic management and has also identified
research priorities for LTBI [8]. We are interested in
whether publication trends specifically for LTBI are on par
with WHO’s recommendations, and also whether the research gaps prioritized by WHO are being addressed across
countries. This study therefore aimed to investigate the research trends in LTBI at the global level and to analyze
gaps in research emphasis in selected countries.
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1995, we found no more than three LTBI-related articles
published per year [12].
Research area grouping process

We exported the list of publications resulting from the
Web of Science into the InCites™ (Clarivate Analytics)
platform for further grouping. Each article was assigned
by the Web of Science to one or multiple subject categories [13]. To ensure each subject category could only be
assigned to one research area, we then followed the protocol published in a previous paper [13] to group the Web
of Science’s subject categories into three research areas
[14]: (A) laboratory sciences, which includes fundamental
research (or basic science) and vaccines; (B) clinical research, which includes diagnostics and treatments; and
(C) public health research, which includes epidemiology,
operational research, and public health. All three research
areas combined encompass the six research priorities
identified by WHO’s international roadmap for TB research [15], namely epidemiology, fundamental research,
research and development of new drugs, research and development of new diagnostics, research and development
of new vaccines, and operational and public health research. The first step was double-blind classification of
subject categories by two researchers (76% agreement).
The second step was an independent classification, without knowing assignment results, for disputed cases by a
senior researcher and reached 98% agreement. The final
step was a meeting among all three researchers to assign
the remaining 2% based on consensus. Additional file 1
shows the assignments of subject categories to the three
areas: laboratory (n = 32), clinical (n = 30), and public
health (n = 47). We excluded subject categories irrelevant
to the three research areas from further statistical analysis.

Methods
Search terms, data source, and study period

Statistical analysis

To find LTBI-related research articles, we reviewed previous systematic reviews on LTBI to define our search
terms [9, 10]. We then searched the Web of Science™
(Clarivate Analytics) with the search terms (“latent tuberculosis” OR “LTBI” OR “latent TB”) entered under
the Topic search field, which searches Title, Abstract,
Author Keywords, and Keyword Plus fields [11]. To find
overall TB-related research articles, we entered the
search terms (“tuberculosis” OR “TB”) under the Title
search field, following the methods of a similar study on
TB research [5]. Restricting the search to only the Title
field helps to minimize false positive search results. We
included original scientific articles and reviews (articles,
hereinafter) with year of publication during the period
1995–2018. We began the search with the year 1995 for
two reasons. First, 1995 is when WHO launched DOTS
(or Directly Observed Treatment, Short Course) as the
recommended strategy for TB control. Second, prior to

We calculated two rates to compare the number of
LTBI-related articles to the number of all articles and to
the number of all TB-related articles, respectively. Rate 1
was calculated by first dividing the number of LTBIrelated articles (area-specific and all three areas) by the
total number of scientific articles (area-specific and all
three areas) for each year, and then averaging the results
over 24 years and multiplying by 1000. The unit of Rate
1 is ‰ per year. Rate 2 was calculated by replacing the
denominator to the number of TB articles and multiplier
to 100. Thus, the unit of Rate 2 is % per year.
We calculated the trend in the global proportion of
LTBI-related articles out of all published articles (a number available from InCites) and all TB-related articles,
respectively, in each research area separately and in the
three areas combined, from 1995 through 2018. We hypothesized that a trend may have at most four significant
changes [16] and thus applied the joinpoint regression
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model with autocorrelation errors to evaluate the best
number of joinpoints and their locations on a trend [17].
Bayesian information criterion were used to determine
the better model with the best number of joinpoints.
Additional file 2 shows the test results for number of
joinpoints. The model can be expressed as a log-linear
regression where the natural logarithm of publication
rate (i.e., the number of LTBI-related articles divided by
the number of all articles and all TB-related articles) was
predicted by a calendar time variable (1 = 1995, 2 = 1996,
..., 24 = 2018). When the number of joinpoints and their
locations were determined, we estimated two kinds of
average annual percent change (AAPC, a weighted average of yearly change [18]) from 1995 to 2018: one is the
average percent change per year in the proportion of
LTBI-related articles relative to all articles (AAPC 1),
and another is the average percent change per year in
the proportion of LTBI-related articles relative to all TBrelated articles (AAPC 2). Both AAPC 1 and AAPC 2
were derived in each research area and in the three areas
combined. The model fitting and AAPC calculations
were accomplished using the Joinpoint Regression Program version 4.7.0.0 (National Cancer Institute, United
States).
Separately, we selected the top 13 countries publishing
LTBI research, which accounted for 80.4% of LTBI-related
articles published during the study period, and repeated
the above analyses. In addition, we performed the generalized additive mixed model on the data from these 13
countries to examine the heterogeneity in the publication
rate of LTBI-related articles relative to all articles and all
TB-related articles as well as the rate of TB-related articles
relative to all articles, using R studio version 1.0.153 (R

Page 3 of 10

Foundation for Statistical Computing, Austria) [19]. Our
model can be expressed as the following equation:
Inðμit Þ ¼ α þ αi þ f ðtÞ þ offset
where μit denotes the expected number of LTBIrelated articles in country i at calendar time t following
a Poisson distribution; α is the fixed intercept, and αi is
the random intercept to account for the initial disparities
at the country level; f(t) denotes a cubic spline to control
for temporal autocorrelation [20–22]; and offset denotes
the natural logarithm of all articles or all TB-related articles in each country per year. The estimated αi can be
transformed by an exponential function to explain the
rate ratio (RR) of LBTI-related articles published in one
country compared to those published in all 13 countries.
The 95% confidence interval of the RR was calculated
for each country.

Results
Global trends

From 1995 to 2018, a total of 4404 LTBI-related articles
were identified in the Web of Science. From these, 4352
articles (98.8%) with information on the year of publication, country of authors, and Web of Science subject categories were imported to InCites and classified into at
least one research area.
The number of articles consistently trended upward
for all, all TB-related, and specifically LTBI-related research (Fig. 1). The proportion of all articles that were
LTBI-related increased from 0.07 per 10,000 in 1995 to
3.84 per 10,000 in 2018. The proportion of TB-related
articles that addressed LTBI also increased, from 0.42%

Fig. 1 Trend in number and proportion of articles related to latent tuberculosis infection (LTBI), 1995–2018. Articles were defined as articles or
reviews belonging to any of the three research areas (see Additional file 1) in InCites™ (Clarivate Analytics)
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in 1995 to 13.66% in 2018. The growth in the proportion
of LTBI-related articles (proportion 2 in Fig. 1) was faster from 1995 to 2008 and slowed afterward.
Among all articles published between 1995 and 2018
in all countries in the three research areas, the largest
proportion were in the laboratory sciences area, followed
by clinical research and public health (Fig. 2a). The proportions of published articles in the laboratory and clinical areas decreased over time, whereas the proportion
published in the public health area increased, showing a
narrowing gap among the three research areas. For TBrelated articles in all countries (Fig. 2b), the laboratory
area remained the largest proportion and grew over
time, leading to a widening gap between it and the other
two areas. For LTBI-related articles in all countries (Fig.
2c), the proportions published in the three areas fluctuated before 2003 due to the small number of articles
overall (N < 50 for the three research areas combined).
Although the proportion in the laboratory area was the
smallest until 2011, it grew over time after that and narrowed the gap between laboratory publications and publications in the other two areas. The average proportions
of LTBI-related articles during the study period were
41.4% in laboratory, 48.8% in clinical, and 42.8% in public health (Table 1, All countries, Proportion).
When we compared the number of LTBI-related articles
to the number of all articles, 1995–2018, the average rates
were highest in the clinical research area (0.28‰/yr),
followed by public health (0.26‰/yr) and laboratory sciences (0.18‰/yr) areas (Table 1, Rate 1). In growth over
time, the AAPC showed a significant increase in all three
areas, with the highest AAPC in laboratory (38.2%/yr),
followed by public health (22.9%/yr) and clinical (15.1%/yr)
(Table 1, AAPC 1). Similar patterns were observed when we
compared the number of LTBI-related articles to the number of all TB-related articles (Table 1, Rate 2 and AAPC 2).

Top 13 countries

For the average number of LTBI-related articles to all
articles published in the top 13 countries, we found
similar patterns in proportions (clinical > public health >
laboratory), rates (clinical > public health > laboratory),
but different patterns for AAPC 1 (public health > clinical > laboratory) and AAPC 2 (public health > laboratory > clinical) (Table 1).
We found diverse patterns for the individual countries,
however. When we compared the proportions of LTBI
publications by country, the clinical area was dominant in
seven countries (led by South Korea’s 61.3%), laboratory
dominant in four countries (led by China’s 62.9%), and
public health dominant in two countries (the United
States and Brazil). We identified five countries with one
research area that had a proportion either 10% lower or

Page 4 of 10

10% higher than those of the other two research areas:
Canada, with a lower proportion of laboratory publications (27.5%); China and India, with higher proportions of
laboratory publications (62.9 and 60.3%); and France and
South Korea, with higher proportions of clinical publications (53.5 and 61.3%).
Among the 13 countries, seven had the highest rates of
LTBI-related articles to all articles in the public health
area, while the other six had the highest rates in the clinical area (Table 1, Rate 1). For the rate of LTBI-related articles to all TB-related articles (Table 1, Rate 2), only three
countries had the highest rates of LTBI-related articles in
public health, whereas the other ten countries had the
highest rates in clinical (led by Canada at 22.0%/yr).
The AAPC of LTBI-related articles relative to all articles among the top 13 countries (Table 1, AAPC 1)
showed significant increases in 12 countries in laboratory, eight countries in clinical, and seven countries in
public health. As for the AAPC of LTBI-related relative
to TB-related articles (Table 1, AAPC 2), significant increases were observed in 12 countries in laboratory, nine
countries in clinical, and six countries in public health.
Figure 3A shows the RR in TB-related articles out of
all articles for each of the individual 13 countries compared to the average rate across the 13 countries, for
each research area (Fig. 3Ab, 3Ac, 3Ad) and in the three
areas combined (Fig. 3Aa), after controlling for temporal
variation. Countries with significantly higher RRs included South Africa (in the three research areas combined with RR = 8.28, 95% CI 5.68 to 12.08 and in the
individual areas), India (in all three areas combined with
RR = 2.53, 95% CI 1.74 to 3.69 and the individual areas),
and Brazil (in public health). The lowest RR was observed in Germany, across all research areas.
When the LTBI-related articles were analyzed (Fig. 3B),
South Africa had the highest RRs and China had the
lowest RRs across all research areas. Figure 3C shows
the RR in LTBI-related articles out of all TB-related articles, and here we observed different patterns: Countries
with significantly higher RRs included Italy (in the three
areas combined with RR = 1.95, 95% CI 1.45 to 2.63 and
the individual areas), Spain (in the three areas combined
with RR = 1.53, 95% CI 1.13 to 2.07 and the individual
areas), Canada (in the three areas combined, clinical,
and public health), and South Korea (in public health).
The lowest RRs were observed in India (in the three
areas combined, laboratory, and clinical) and South Africa (in public health).

Discussion
We conducted a bibliometric analysis on LTBI-related
articles, analyzing publication trends (both globally and
among the top 13 countries) of LTBI-related articles
relative to all scientific and all TB-related publications
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Fig. 2 Trends in number and proportion of articles published by research area, 1995–2018. Articles were defined as articles or reviews belonging
to any of the three research areas (see Additional file 1 in InCites™ (Clarivate Analytics)
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The orders of the top 13 countries are listed based on the total number of LTBI-related articles published 1995–2018
a
n = Number of LTBI-related articles published 1995–2018, defined as articles or reviews belonging to any of three research areas (see Additional file 1) in InCites™ (Clarivate Analytics). Because each
article may be assigned to more than one research area and country in InCites, duplicates were excluded when the three areas were combined
b
Rate 1 (unit: ‰ per year) was calculated by first dividing the number of LTBI-related articles (area-specific and all three areas) by the total number of scientific articles (area-specific and all three areas)
for each year, and then averaging the results over 24 years and multiplying by 1000 (thus the unit is ‰ per year, which is a rate rather than a proportion)
c
Rate 2 (unit: % per year) was calculated by first dividing the number of LTBI-related articles (area-specific and all three areas) by the number of TB articles (area-specific and all three areas) for each
year, and then averaging the results over 24 years and multiplying by 100 (thus the unit is % per year, which is a rate rather than a proportion)
d
AAPC = Average annual percent change (unit: % per year). AAPC 1 represents the average percent change per year in the proportion of LTBI-related articles relative to all articles. AAPC 2 represents the
average percent change per year in the proportion of LTBI-related articles relative to all TB-related articles
e
Proportion (unit: %) was calculated by dividing the number of area-specific LTBI-related articles by the number of LTBI-related articles across all three areas, over 24 years. Because the sum of the
number of articles in each of the three research areas exceeded the number of articles across all three areas (excluding duplicates), the sum of the proportions of the three research areas may
exceed 100%
f
p-value less than 0.05
g
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Table 1 Trends in LTBI-related articles published 1995–2018 overall and in the top 13 countries, by research area
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Fig. 3 Rate ratios of TB- and LTBI-related articles in each research area by country, compared to the average across countries. The orders of the 13
countries are listed based on the total number of LTBI-related articles published 1995–2018 (in line with Table 1). The red dotted line represents the
average across the 13 countries with the highest publication numbers. We estimated the rate ratios by using a generalized additive mixed model with
a Poisson distribution and comparing the rate of LTBI-related articles in each research area in each country, and across all three research areas
combined, to the average rate across the 13 countries combined, i.e., rate ratio = 1, after adjusting for temporal variation

from 1995 to 2018. Globally, we found that the average
proportions of LTBI-related publications against both all
scientific and all TB-related publications were similar in
all three research areas (laboratory, clinical, and public
health), ranging between 41 and 49%. LTBI-related publications in all three areas significantly increased over
time. This could be partly due to the challenges of LTBI
case detection and ascertainment [23]. People with LTBI
tend to be asymptomatic, with high rates of infection occurring among specific risk groups, particularly household contacts of TB cases [8]. Contact investigation at
the community or population level is thus necessary to
identify candidates for LTBI testing and treatment [8].
Identifying and initiating treatment among groups of
people at high risk of developing TB disease is one of
the priorities for TB elimination [3].
All the top 13 countries that we have identified as being involved in most LTBI-related research have also
contributed funding to TB research and development
(R&D), either as an individual country or as part of an
association, such as the European Union or BRICS
(Brazil, Russia, India, China, and South Africa) [24]. Our

findings are also in line with a previous bibliometric analysis of overall TB research that found the same countries to be also the top publishing countries for overall
TB research [5]. In 2017, the largest funder for TB R&D
was the United States, followed by the European Union
and the United Kingdom [24]. The list of top funders
also includes four BRICS countries (i.e., South Africa,
China, India, and Brazil). BRICS accounted for 53% of
the global funding for TB and 47% of the world’s notified TB cases in 2018 [1]. South Africa, China, India,
and Brazil are also part of the top 30 high TB burden
countries (i.e., those with TB incidence of > 100 per 100,
000 population) as defined by WHO [25].
Even though BRICS countries are in the top 13 countries for LTBI-related research, further analysis found
that they in fact placed more emphasis on TB research
than specifically on LTBI research. In particular, South
Africa, India, and Brazil had significantly higher RRs for
TB-related publications relative to all scientific publications. One possible explanation lies in the TB burden of
each country: All three countries have high TB incidence
rates (520, 199, and 45 per 100,000 population in South
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Africa, India, and Brazil, respectively in 2018) and are
among the top 30 high TB burden countries [25]. All
three countries also have a high burden of HIV, and the
presence of this infection is known to be a predisposing
and precipitating factor for the development of TB [23].
TB is a major occupational disease among mineworkers
in South Africa, whose TB incidence rates are 3 to 7
times higher than that of the country’s general population [26]. Recognizing the importance of TB, these countries have invested significantly in TB R&D. India has
publicly recognized the financial implications of the TB
burden in the country, and its government has pledged
to fund TB research activities [27]. South Africa invests
more than 0.1% of the country’s gross domestic product
to TB R&D (called the 0.1% fair share target) [24]. This
could explain why we found high RRs of both TB- and
LTBI-related research, relative to all scientific publications, in South Africa.
Also, we found that South Africa and India had significantly low RRs for LTBI-related research publications relative to all TB-related publications. In addition to being
high TB burden countries as mentioned earlier, both
countries are also among the top TB/HIV (incidence rate
of 306 and 6.8 per 100,000 population, for South Africa
and India respectively) and multidrug-resistant TB (incidence rate of 19 and 9.6 per 100,000 population, for South
Africa and India respectively) burden countries [1]. Hence,
this finding could be due to them prioritizing TB disease
and not LTBI. Yet one reason for the slow progress against
TB is the presence of a huge and persistent reservoir of
LTBI. Despite the fact that most high and low TB burden
countries already have a national policy addressing LTBI
management in specific risk groups, most TB control programs in low- and middle-income countries have focused
almost exclusively on detection and treatment of active TB
cases [3]. Taken together, our findings suggest that high
TB burden countries tend to prioritize TB-related research, which is unsurprising given the challenges of TB
treatment and control in such countries. These countries
also need to tackle issues of high HIV incidence, which is
a precipitating factor in developing TB disease.
When using all TB-related publications as the denominator for RR analysis, we observed that Canada, Italy,
and Spain had significantly higher RRs of LTBI-related
publications for the three research areas combined. All
three countries have been identified as low TB burden
countries (i.e., those with TB incidence of < 10 per 100,
000 population) based on recent surveillance reports [28,
29]. As proposed in WHO’s framework towards TB
elimination for low-incidence countries [30], preventing
the progression of LTBI to TB disease (through detection and early treatment of LTBI cases) will play a crucial role in eliminating TB in these countries. This could
explain these countries’ emphasis on LTBI research. In
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particular, Italy has highlighted the prioritization of
LTBI testing and treatment in high-risk groups as one of
its eight main interventions to eliminate TB [31].
From the same analysis, we observed high RRs of LTBI
compared to TB publications for South Korea in the
public health area. South Korea is the only Organisation
for Economic Co-operation and Development country
with high TB incidence, and since 2013 it has been
implementing a five-year TB control plan that emphasizes extensive contact investigation and LTBI management [32]. This could explain the increase in public
health publications on LTBI in South Korea.
Although we observed an overall increasing trend of
LTBI-related publications for the public health area,
comparing the Rate 2 results across the three research
areas in each of the top 13 countries tells us another
story. That is, only three countries (China, India, and
South Korea) have highest rates (4.9, 3.8, and 11.2% per
year, respectively) for public health-related research
among the three research areas analyzed. As mentioned
earlier, community studies are important to determine
the burden of LTBI to allow the implementation of locally tailored interventions. Taken together, our findings
suggest that more studies focusing on LTBI are needed,
particularly on public health-related research, not only
in low TB burden countries but also in high TB burden
countries with rapidly expanding economies. Indeed, determining the burden of LTBI in various geographical
setting and identifying population groups at-risk of progression to TB disease are the two research public
health-related priorities highlighted by WHO [3]. Modeling studies have shown that implementing a combination of interventions (i.e., to prevent TB infections in
addition to detecting and treating TB patients) results in
major reductions in TB burden [33, 34] and thus helps
to reach the targets set by the End TB Strategy.
This study has several limitations. First are the methodology limitations mentioned in a previous bibliometric
analysis [13], including potential misclassifications when
assigning articles into research areas or countries as well
as underappreciation of countries that have only recently
begun TB research and with few accumulated publications. We could reduce misclassification bias by assigning
each article to multiple subject categories and multiple
countries, but bear the side effect that the sum of the
number of articles in the three research areas and multiple
countries would exceed the sum of the three-areascombined and the all-countries-combined [13]. We have
limited information for countries just begun TB research
in recent years. Similarly, countries published research
findings in non-English journals or new journals without
impact factors were not captured in our analysis. We suggest a separate analysis after a certain period of follow-up
to consider these potential changes in the future. Next, for
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this study we classified articles into three broad research
areas instead of the six specific research priorities identified by WHO’s international roadmap for TB research
[15]. Our classification is not fully representative of each
priority in the roadmap, but is still in line: the laboratory
sciences area covers the priorities of fundamental research
and vaccines, the clinical research area covers diagnosis
and treatment, and the public health area covers epidemiology and operation and public health research. Hence,
the broadly categorized trends observed in our study
could still reflect the research trends proposed by WHO.
Using fewer categories, meanwhile, increased the number
of LTBI papers in each area and allowed us to perform
statistical analyses. Finally, we extracted data on the 13
countries that had the most publications regarding LTBI.
However, TB burden generally affects developing countries, where resources for research could be scarce, and
this might limit the generalizability of our interpretation
to these countries.

Conclusions
Globally, there has been positive progress towards more
LTBI-related research, with the number of publications
growing annually from 1995 to 2018. Discrepancies
across countries exist in the emphasis on either TB or
LTBI research. High TB burden countries have been
more involved in overall TB-related research, whereas
low TB burden countries have focused more on LTBIrelated research. Given the potential benefits of LTBI research to reducing TB incidence, our findings suggest
that high TB burden countries should place more emphasis on research related to LTBI.
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